31m
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an ...
Who could be the next Indiana? Who might flop in 2026? Our writers weigh in with their takeaways from 2025 and thoughts on what's ahead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback